相关实验视频
Updated: Jul 14, 2026
06:27
Fast and Accurate Exhaled Breath Ammonia Measurement
Published on: June 11, 2014
13.9K
用呼吸酒精计优化血液酒精度测量及其在评估CYP2E1活动中的初步应用
Jiayi Zhang1, Yingqi Hu1, Ziqi Jin1
1Department of Pharmacology, Baotou Medical College, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou, China.
PloS one
|October 31, 2025
概括
一种新的呼吸酒精检测方法提供了一种简单的,非侵入性的方法来评估大鼠肝脏CYP2E1活性. 这种方法为评估肝酶功能的传统,更复杂的方法提供了可行的替代方案.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 生物化学 生物化学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 乙醇的新陈代谢主要由CYP2E1和酒精脱酶控制.
- 在老鼠中使用乙醇作为探针评估CYP2E1活性是具有挑战性的.
- 目前的方法,如HPLC检测氧是劳动密集型和昂贵的.
研究的目的:
- 开发和优化一种快速,非侵入性的方法来检测大鼠血液中酒精度 (BAC).
- 应用此方法对肝脏CYP2E1活性进行初步评估.
- 调查乙醇作为潜在的探针基质用于CYP2E1活性评估.
主要方法:
- 在Sprague-Dawley大鼠中诱导了免疫介导的肝损伤.
- 使用呼吸酒精计测量血中酒精度 (BAC),并通过气相色谱验证.
- 通过细分BAC-时间曲线来评估CYP2E1活性,并通过HPLC分析氧代谢来证实.
主要成果:
- 在老鼠中成功诱导免疫性肝损伤.
- 呼吸酒精计的测量准确地反映了BAC,并显示肝损伤小鼠的酒精代谢减少.
- 与对照组相比,HPLC分析证实肝损伤的老鼠中CYP2E1活性显著降低.
结论:
- 呼吸酒精检测方法是一种简单的,非侵入性的替代方法,用于评估肝脏CYP2E1代谢活性.
- 与现有技术相比,这种方法提供了一种快速有效的方法.
- 这项研究验证了乙醇作为CYP2E1活性评估的探针的实用性 in vivo.
相关概念视频
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...